Details of the Drug

General Information of Drug (ID: DM5JVS3)

Drug Name
Isoniazid
Synonyms
Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.
Indication
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B1Z Approved [1]
Therapeutic Class
Antitubercular Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 137.14
Topological Polar Surface Area (xlogp) -0.7
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.4 mL/min/kg [4]
Elimination
7% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 - 1.6 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 72.91702 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.82 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 153 mg/mL [2]
Chemical Identifiers
Formula
C6H7N3O
IUPAC Name
pyridine-4-carbohydrazide
Canonical SMILES
C1=CN=CC=C1C(=O)NN
InChI
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
InChIKey
QRXWMOHMRWLFEY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3767
ChEBI ID
CHEBI:6030
CAS Number
54-85-3
DrugBank ID
DB00951
TTD ID
D09XQF
VARIDT ID
DR00422
INTEDE ID
DR0886
ACDINA ID
D00332

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Fatty acid synthetase I (Bact inhA) TTVTX4N INHA_MYCTU Inhibitor [7], [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [10]
Catalase-peroxidase (katG) DEAGY5M KATG_SYNE7 Substrate [11]
Arylamine N-acetyltransferase (NAT) DEXCQTM A0A3P8LE58_TSUPA Substrate [12], [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isoniazid
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Rifampin DMA8J1G Minor Increased risk of hepatotoxicity by the combination of Isoniazid and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [30]
Coadministration of a Drug Treating the Disease Different from Isoniazid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [31]
Midostaurin DMI6E0R Moderate Decreased metabolism of Isoniazid caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Isoniazid caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [33]
Ivabradine DM0L594 Moderate Decreased metabolism of Isoniazid caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [33]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Isoniazid caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [34]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [35]
Cilostazol DMZMSCT Moderate Decreased metabolism of Isoniazid caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [36]
Budesonide DMJIBAW Moderate Decreased metabolism of Isoniazid caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [37]
Aminophylline DML2NIB Moderate Decreased metabolism of Isoniazid caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [38]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Isoniazid caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [33]
Cariprazine DMJYDVK Moderate Decreased metabolism of Isoniazid caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [33]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Isoniazid and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [39]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Isoniazid caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Palbociclib DMD7L94 Moderate Decreased metabolism of Isoniazid caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Moderate Decreased metabolism of Isoniazid caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Macitentan DMP79A1 Moderate Decreased metabolism of Isoniazid caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [41]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Isoniazid caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [42]
PF-04449913 DMSB068 Moderate Decreased metabolism of Isoniazid caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [43]
Anisindione DM2C48U Moderate Decreased metabolism of Isoniazid caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [44]
Ulipristal DMBNI20 Minor Decreased metabolism of Isoniazid caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [33]
Levobupivacaine DM783CH Moderate Decreased metabolism of Isoniazid caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [33]
Halothane DM80OZ5 Major Increased risk of hepatotoxicity by the combination of Isoniazid and Halothane. Corneal disease [9A76-9A78] [45]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Isoniazid caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [38]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Isoniazid caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [33]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Isoniazid caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [46]
Escitalopram DMFK9HG Moderate Decreased metabolism of Isoniazid caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [47]
Ospemifene DMC4GEI Moderate Decreased metabolism of Isoniazid caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [48]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Isoniazid caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Clonazepam DMTO13J Moderate Decreased metabolism of Isoniazid caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Phenobarbital DMXZOCG Minor Decreased metabolism of Isoniazid caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Cannabidiol. Epileptic encephalopathy [8A62] [33]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Isoniazid caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [51]
Solifenacin DMG592Q Moderate Decreased metabolism of Isoniazid caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [52]
Mirabegron DMS1GYT Minor Decreased metabolism of Isoniazid caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [53]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Isoniazid caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [54]
Itraconazole DMCR1MV Moderate Increased metabolism of Isoniazid caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Ketoconazole DMPZI3Q Moderate Increased metabolism of Isoniazid caused by Ketoconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Ripretinib DM958QB Moderate Decreased metabolism of Isoniazid caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [31]
Avapritinib DMK2GZX Moderate Decreased metabolism of Isoniazid caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [33]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Brentuximab vedotin. Hodgkin lymphoma [2B30] [55]
MK-1439 DM215WE Minor Decreased metabolism of Isoniazid caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Dolutegravir DMCZGRE Minor Decreased metabolism of Isoniazid caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Lopinavir DMITQS0 Minor Decreased metabolism of Isoniazid caused by Lopinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Isoniazid caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Abacavir DMMN36E Minor Increased plasma concentrations of Isoniazid and Abacavir due to competitive inhibition of the same metabolic pathway. Human immunodeficiency virus disease [1C60-1C62] [58]
Atazanavir DMSYRBX Moderate Decreased metabolism of Isoniazid caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Maraviroc DMTL94F Moderate Decreased metabolism of Isoniazid caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Isoniazid and Mipomersen. Hyper-lipoproteinaemia [5C80] [61]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Isoniazid and Teriflunomide. Hyper-lipoproteinaemia [5C80] [47]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Isoniazid and BMS-201038. Hyper-lipoproteinaemia [5C80] [62]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Isoniazid caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [33]
Retapamulin DM9JXB7 Minor Decreased metabolism of Isoniazid caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [63]
Lesinurad DMUR64T Moderate Decreased metabolism of Isoniazid caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [64]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Isoniazid caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Ramelteon DM7IW9J Moderate Decreased metabolism of Isoniazid caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [65]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Isoniazid caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [66]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Isoniazid caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [67]
Quazepam DMY4D87 Moderate Decreased metabolism of Isoniazid caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
Estazolam DMZGXUM Moderate Decreased metabolism of Isoniazid caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
Alosetron DML2A03 Moderate Decreased metabolism of Isoniazid caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [68]
Naloxegol DML0B41 Minor Decreased metabolism of Isoniazid caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [69]
Pemigatinib DM819JF Moderate Decreased metabolism of Isoniazid caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [33]
Brigatinib DM7W94S Moderate Decreased metabolism of Isoniazid caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Ceritinib DMB920Z Moderate Decreased metabolism of Isoniazid caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [70]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Isoniazid caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [71]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Isoniazid caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [72]
Osimertinib DMRJLAT Moderate Decreased metabolism of Isoniazid caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [73]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Isoniazid caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [74]
Selpercatinib DMZR15V Moderate Decreased metabolism of Isoniazid caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [33]
Halofantrine DMOMK1V Major Decreased metabolism of Isoniazid caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [75]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [76]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Idelalisib. Mature B-cell leukaemia [2A82] [77]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Isoniazid caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
IPI-145 DMWA24P Moderate Decreased metabolism of Isoniazid caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [78]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Isoniazid caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [79]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Isoniazid caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [80]
Selumetinib DMC7W6R Moderate Decreased metabolism of Isoniazid caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [81]
Ubrogepant DM749I3 Moderate Decreased metabolism of Isoniazid caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [82]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Isoniazid caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [42]
Flibanserin DM70DTN Moderate Decreased metabolism of Isoniazid caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [83]
Panobinostat DM58WKG Moderate Decreased metabolism of Isoniazid caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [84]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Isoniazid and Thalidomide. Multiple myeloma [2A83] [85]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Isoniazid caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Isoniazid caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Entrectinib DMMPTLH Moderate Decreased metabolism of Isoniazid caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [86]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Isoniazid caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [87]
Olaparib DM8QB1D Moderate Decreased metabolism of Isoniazid caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [88]
Safinamide DM0YWJC Moderate Additive serotonergic effects by the combination of Isoniazid and Safinamide. Parkinsonism [8A00] [89]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Isoniazid caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [31]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Isoniazid caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [90]
Lefamulin DME6G97 Moderate Decreased metabolism of Isoniazid caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [91]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Isoniazid caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [92]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Isoniazid caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [93]
Silodosin DMJSBT6 Moderate Decreased metabolism of Isoniazid caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [94]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Isoniazid caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [95]
Everolimus DM8X2EH Moderate Decreased metabolism of Isoniazid caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [96]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Isoniazid and Leflunomide. Rheumatoid arthritis [FA20] [47]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Isoniazid caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [97]
Thiothixene DMDINC4 Minor Decreased metabolism of Isoniazid caused by Thiothixene. Schizophrenia [6A20] [98]
Asenapine DMSQZE2 Moderate Decreased metabolism of Isoniazid caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [99]
Pimozide DMW83TP Major Decreased metabolism of Isoniazid caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [31]
LDE225 DMM9F25 Moderate Decreased metabolism of Isoniazid caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [100]
Larotrectinib DM26CQR Moderate Decreased metabolism of Isoniazid caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Isoniazid and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [33]
Armodafinil DMGB035 Minor Decreased metabolism of Isoniazid caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
LEE011 DMMX75K Moderate Decreased metabolism of Isoniazid caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Calcium sulfate dihydrate E00315 24928 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Isoniazid 100 mg tablet 100 mg Oral Tablet Oral
Isoniazid 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
8 Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents. Curr Drug Targets. 2007 Mar;8(3):399-411.
9 Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Curr Top Med Chem. 2007;7(5):499-507.
10 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
11 Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. FEBS Lett. 2015 Jan 2;589(1):131-7.
12 The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog. World J Microbiol Biotechnol. 2019 Oct 31;35(11):174.
13 Complete genome sequence of Tsukamurella paurometabola type strain (no. 33). Stand Genomic Sci. 2011 Jul 1;4(3):342-51.
14 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
15 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
16 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
17 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
18 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
19 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
20 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
21 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
22 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
23 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
24 Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
25 Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
26 Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
27 SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
28 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
29 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
30 Askgaard DS, Wilcke T, Dossing M "Hepatotoxicity caused by the combined action of isoniazid and rifampicin." Thorax 50 (1995): 213-4. [PMID: 7701468]
31 Cerner Multum, Inc. "Australian Product Information.".
32 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
35 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
36 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
37 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
38 Dal Negro R, Turco P, Trevisan F, De Conti F "Rifampicin-isoniazid and delayed elimination of theophylline: a case report." Int J Clin Pharmacol Res 8 (1988): 275-7. [PMID: 3182118]
39 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
40 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
42 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
43 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Eade NR, McLeod PJ, MacLeod SM "Potentiation of bishydroxycoumarin in dogs by isoniazid and paminosalicylic acid." Am Rev Respir Dis 103 (1971): 792-9. [PMID: 4103778]
45 Bartelink AK, Lenders JW, van Herwaarden CL, et al "Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy." Tubercle 64 (1983): 125-8. [PMID: 6612792]
46 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
47 Canadian Pharmacists Association.
48 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
49 Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
50 Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
51 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
52 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
53 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
54 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
55 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
56 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
57 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
58 Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
59 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
60 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
62 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
63 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
64 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
66 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
67 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
68 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
69 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
71 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
72 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
75 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
76 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
77 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
78 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
79 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
81 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
82 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
83 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
84 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
85 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
86 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
87 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
88 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Xadago (safinamide). US WorldMeds LLC, Louisville , KY.
90 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
91 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
92 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
93 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
95 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
96 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
97 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
98 Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW "Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables." J Clin Psychopharmacol 11 (1991): 296-301. [PMID: 1765572]
99 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
100 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.